Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 4/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | ULK1 | O75385 | 6/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL1098913 | 0.85 | CDK8 (0.46) | CDK8AXLULK1RIPK1KDR | |
| Ethoxycarbonyl Group SCHEMBL28774140 | 0.82 | CDK8 (0.41) | CDK8AXLULK1PIK3CDPIK3CA | |
| SCHEMBL27943918 | 0.82 | PIK3CD (0.67) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL84144 | 0.81 | CDK8 (0.50) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL14146332 | 0.79 | RIPK1 (0.49) | CDK8AXLPIK3CDPIK3CAPIK3CB | |
| SCHEMBL21560915 | 0.79 | CDK8 (0.47) | CDK8AXLULK1PIK3CDPIK3CA | |
| SCHEMBL3349140 | 0.78 | PIK3CD (0.43) | CDK8AXLULK1PIK3CDPIK3CA | |
| SCHEMBL3349147 | 0.78 | PIK3CD (0.43) | CDK8AXLULK1PIK3CDPIK3CA | |
| SCHEMBL20685730 | 0.76 | CDK8 (0.45) | CDK8AXLULK1PIK3CDPIK3CA | |
| SCHEMBL18427601 | 0.76 | CDK8 (0.45) | CDK8AXLPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294522-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2024-09-05 | — | — | US | claimed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| CN-118715221-A | Tricyclic compounds and uses thereof | 希格生科（深圳）有限公司 | 2024-09-27 | — | — | CN | disclosed |
| EP-4271664-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116867758-A | IRAK degradation agents and uses thereof | 凯麦拉医疗公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023143354-A1 | TRICYCLIC COMPOUND AND APPLICATION THEREOF | 希格生科（深圳）有限公司 | 2023-08-03 | — | — | WO | disclosed |
| US-20230101353-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022199599-A1 | ACRYLOYL-SUBSTITUTED COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 凯复(苏州)生物医药有限公司 | 2022-09-29 | — | — | WO | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| CN-101678022-A | 5-cyano-4- (pyrrolo [2,3b ] pyridin-3-yl) pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMA | 2010-03-24 | — | — | CN | disclosed |
| CN-101646653-A | Fused ring compounds as partial agonists of ppar-gamma | TAKEDA PHARMACEUTICAL JP | 2010-02-10 | — | — | CN | disclosed |
| EP-2124951-A1 | 5-CYAN0-4- (PYRROLO Ý2, 3B¨PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| CN-101522678-A | Novel imidazolinone derivatives, their preparation as medicaments, pharmaceutical compositions, their use as inhibitors of kinases, in particular CDC7 | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | CN | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| WO-2008079346-A1 | 5-CYAN0-4- (PYRROLO [2, 3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079346-A1 | 5-CYAN0-4- (PYRROLO [2, 3B] PYRIDINE-3-YL) -PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | CDK8 2641/4885AXL 3934/4885ULK1 2627/4885 |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CDK8 646/4885AXL 356/4885ULK1 755/4885 |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | CDC7, CDK7, CDK17 | CDK8 119/4885AXL 533/4885ULK1 64/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CDK8 646/4885AXL 356/4885ULK1 755/4885 |
| US-20240294522-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | GRK5, GRK3, GRK4 | CDK8 1716/4885AXL 2226/4885ULK1 579/4885 |
| US-20230101353-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CDK8 646/4885AXL 356/4885ULK1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.